
Our response to the COVID-19 pandemic
Supporting our partners to provide the best possible care for patients
We are committed to support front-line healthcare professionals and help them to deliver high-value critical care to patients at each stage of COVID-19 disease management: diagnosis, prognosis, therapy and follow-up.
The coronavirus (SARS-CoV-2) pandemic continues to spread, confronting healthcare professionals around the world with unprecedented clinical and operational challenges. As they struggle to deal with this extraordinary situation, at the same time they must also continue to care for other patients.
At Siemens Healthineers, we are aware of the urgency and complexity of the current situation, and we are working hard to provide the best possible support to healthcare providers at each stage of COVID-19 patient care: diagnosis, prognosis, therapy and follow-up.
Our aspiration to drive innovations forward so people live healthier and longer lives is more valid today than ever before. We are stepping up as a partner to support healthcare systems helping them to deliver high-value care to patients and families. Please do not hesitate to contact us in case of questions or suggestions.
Due to high demand, availability in certain regions may be affected, please contact your local Siemens Healthineers organization for details.
COVID-19 Response
We support you to provide the best possible care for patients.
In the following overview we want to highlight parts of the portfolio from Siemens Healthineers that can support healthcare providers at each stage of COVID-19 patient care: diagnosis, prognosis, therapy and follow-up.
Clinical
Our medical imaging, laboratory diagnostics and point-of-care testing solutions can support physicians to make a prognosis about the severity of a COVID-19 case, help treat the patient, and assist in the follow-up to find out when the patient has recovered.
Operational
At the same time our digital health solutions, services and consulting can support healthcare providers in protecting healthcare workers and increasing healthcare delivery capacity. For example, our digital services enable medical personnel to operate systems regardless of their location and thus with a potentially lower risk of infection.

- Antigen test
Antigen testing for rapid detection of SARS-CoV-2 virus which causes COVID-191 - Molecular lab test
Real-time PCR detects identify RNA from SARS-CoV-2 (FTD SARS-CoV-2 Assay)2 Immuno/chemistry lab tests
Comprehensive lab testingHematology/hemostasis lab tests
Managing coagulation abnormalities in COVID-19 patients- Blood gas tests
Blood gas systems are used in the management of patients under respiratory distress - X-ray
X-ray systems support initial assessment of severity and monitoring Ultrasound
Fast, simple, and mobile ultrasound imagingCT
Computed Tomography (CT) images used in evaluation of infectious disease- C-Arm
Cios mobile C-arms – an option for lung imaging - Anti-body lab test to help indicate an immune response
- Digital Solutions
Remote care management of potential COVID-19 patients may help free up inpatient capacity Remote operations, services and education
Remote scanning assistance to ensure care continuity- Online education and knowledge resources on COVID-19
- Artificial Intelligence
Supporting radiologists in COVID-19 evaluation by applying Artificial Intelligence to images - Healthcare staff protection and capacity management
Delivering on the need for increased treatment capacity with Rapid Activation Management Consulting Services
COVID-19 Response – Clinical
COVID-19 Response – Operational
Related Products and Topics
Explore our COVID-19 relevant Webinars
Product availability may vary from country to country and is subject to varying regulatory requirements.
CE-IVD labelled for diagnostic use in the EU. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21. U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Visit fast-trackdiagnostics.com for a list of compatible instruments. Customers are responsible for validating the assay on instruments listed in the compatibility list.
In development; not available for sale. Future availability cannot be guaranteed.
Product availability may vary from country to country and is subject to varying regulatory requirements.
Fang et al., Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR, Radiology 2020.
Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. Published online March 25, 2020. doi:10.1001/jamacardio.2020.0950.
Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Published online March 27, 2020. doi:10.1001/jamacardio.2020.1017.
Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Published online March 27, 2020. doi:10.1001/jamacardio.2020.1096.
Not available in all countries.
For research use only. Not for use in diagnostic procedures.
AI-Rad Companion Chest X-ray is currently not for sales in the United States and other selected countries.
A secure VPN connection to the department network is required. Other appropriately trained personnel must be in the room to care for patient, position the patient, and manually start the scan.
The DICOM viewer is not intended for diagnostic display. Due to regulations data exchange between data center regions is restricted. The products/features/service offerings are not commercially available in all countries. If the services are not marketed in countries due to regulatory or other reasons, the service offering cannot be guaranteed. Please contact your local Siemens organization for further details.
Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local Siemens Healthineers organization for further details.
CE-IVD labelled for diagnostic use in the EU. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21. U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The products/features and/or service offerings (here mentioned) are not commercially available in all countries and/or for all modalities. If the services are not marketed in countries due to regulatory or other reasons, the service offering cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
Due to high demand, availability in certain regions may be affected, please contact your local Siemens Healthineers representative for details.